Global Male Cancer Market Receives Boost from Increasing Prevalence of Prostate Cancer

A new study by Transparency Market Research (TMR), titled “Male Cancer Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” presents a complete picture of the market by examining its driving forces, risks and hindrances, opportunities, major trends, and future prospects.

The research report states that the augmenting dominance of unhealthy lifestyles, the rising habit of smoking and drinking, increasing consumption of junk food, obesity, hereditary factors, and the growing exposure to carcinogenic elements have escalated the prevalence cancer among men across the world.

Download Report Brochure For Details Industry Insights:

In this study, testicular cancer, prostate cancer, and penile cancer have been identified as the main types of cancer reported in men. Among these, prostate cancer exhibits the highest prevalence rate. According to the International Journal of Cancer, prostate cancer is the prime cause of death in geriatric males.

On the other hand, testicular cancer is more prevalent in younger males in the age group of 20-40 years. Caucasian males are prone to testicular cancer while it rarely appears in those with Asian or African ethnicity. The treatment of this cancer includes surgery and boasts the highest success rate among male-specific cancer treatments.

Penile cancer is relatively less prevalent globally. However, it has a considerable spread in third world economies. Human papillomavirus (HPV) is the root cause of this disease. The treatment of penile cancer mostly includes antiviral therapy, chemotherapy, and surgical excision.

Further, the report states that the advancements in genomics and proteomics have boosted the market for male-specific cancer therapeutics in the recent times. The increase in research and development activities, leading to advanced treatments for cancerous tumors, is also propelling this market significantly.

On the flip side, the high cost of treatments, together with the increasing incidence of their adverse effect on patients, is likely to limit the global market for male cancer therapeutics over the forecast period. However, high unmet needs in emerging countries, coupled with limited presence of local enterprises, is likely to present lucrative opportunities for international market players, notes the study.

Browse Full Report With TOC:

The competitive landscape prevalent in the global male protest cancer market has also been analyzed in this report on the basis of the performance and the future prospects of key organizations functioning in this market. Abbott Laboratories, Active Biotech, AstraZeneca Plc, Astellas Pharma Inc., Bristol-Myers Squibb, Dendreon Corp., Endo Pharmaceuticals Inc., Ipsen, Johnson & Johnson, Pfizer Inc., Sanofi-Aventis, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Ferring Pharmaceuticals, and Tolmar Inc. are some of the major international companies that are developing treatments and medications for male cancers, states the research report.